Silexion Therapeutics Corp - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SLXN Nasdaq 2830 silexion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Silexion Therapeutics Corp

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Jun 23rd, 2026 6:40 am
Silexion Therapeutics to Attend BIO International Convention 2026 - Jun 16th, 2026 2:30 pm
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - May 26th, 2026 6:30 am
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - May 18th, 2026 6:30 am
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds - May 15th, 2026 6:27 am
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer - May 14th, 2026 7:27 am
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center - May 13th, 2026 6:00 am
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer - Apr 28th, 2026 6:45 am
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Mar 24th, 2026 7:46 am
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Mar 17th, 2026 3:01 pm
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting - Mar 5th, 2026 6:00 am
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - Jan 21st, 2026 6:30 am
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026 - Jan 6th, 2026 5:30 am
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer - Dec 16th, 2025 6:40 am
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Dec 2nd, 2025 6:00 am
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - Nov 26th, 2025 5:30 am
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - Nov 25th, 2025 7:15 am
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 12th, 2025 7:00 am
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer - Sep 30th, 2025 6:40 am
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements - Sep 25th, 2025 6:45 am